A new study finds more rapid recurrence and higher mortality in more advanced stages among never-smokers compared with ever-smokers. What are the implications for screening and management?
Peter Mazzone, MD, MPH, Director of the Lung Cancer program, discusses USPSTF-backed changes to screening eligibility. Who qualifies, and how will this change your practice?
A case highlighting the value of multidisciplinary management of malignant central airway occlusion and demonstrating the critical role interventional pulmonologists can play in cancer care.
Single-fraction SBRT is safe and effective in treating early stage, medically inoperable NSCLC, according to a ten-year retrospective study of 229 patients, the largest single-institution report to date.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic Cancer Center oncologist Nathan Pennell MD, PhD, and other experts provide guidance on caring for lung cancer patients during the COVID-19 pandemic
A prototype blood-based screening test evaluated by Cleveland Clinic researchers and others can accurately detect and localize multiple types of cancer, often before symptoms show. The promising results raise hopes that the assay will help achieve the long-sought goal of population-scale early detection of cancer.
Cleveland Clinic researchers have trained an advanced computer network to find subtle radiation sensitivity features in the CT scans of individual lung cancer patients that can predict the likelihood of successful radiotherapy outcomes. The network can generate a personalized radiation dose plan that reduces the probability of treatment failure to less than 5%.
A lung cancer survivor with abnormal stricture of the trachea and bronchus receives a customized, 3D-printed silicone stent, an approach pioneered at Cleveland Clinic.
Can metastases to the lung occur from cancers that were treated several years ago?
A study recently published in Lancet Oncology found ALT-803 + nivolumab safe and with early signs of efficacy in patients with mNSCLC considered PD-1-treatment resistant.